1. Introduction {#sec1}
===============

Mitochondrial pyruvate metabolism requires transport across the impermeable inner mitochondrial membrane (IMM). Recent work has shown that mitochondrial pyruvate import is mediated by two proteins, the Mitochondrial Pyruvate Carrier 1 and 2 (MPC1 and MPC2), which form a hetero-oligomeric complex in the IMM [@bib1], [@bib2]. Deletion of either MPC1 or MPC2 leads to destabilization and degradation of the complex, effectively resulting in a MPC double knockout and significantly reduced mitochondrial pyruvate uptake [@bib1], [@bib2], [@bib3]. Mice with partial loss of MPC function [@bib4], *Drosophila* with constitutive MPC1 deletion [@bib2], and mammalian cells with MPC knockdown via RNAi [@bib5] are viable and outwardly normal. However, global and constitutive loss of MPC1 [@bib6] or MPC2 [@bib4] in mice leads to lethality at early embryonic stages.

Mitochondrial pyruvate metabolism is thought to play an important role in the ability of pancreatic β-cells to respond appropriately to increased glucose concentrations by secreting insulin [@bib7], [@bib8], [@bib9]. Oxidation of pyruvate by the pyruvate dehydrogenase complex results in increased ATP production, which inhibits ATP-sensitive potassium (K~ATP~) channels, depolarizes the β-cell, and promotes calcium influx to drive insulin release. In addition, several studies have shown that the production of anaplerotic products by pyruvate carboxylation in the mitochondrial matrix promotes insulin granule exocytosis by Ca^2+^-independent mechanisms [@bib7], [@bib10], [@bib11], [@bib12]. Chemical inhibition or RNAi-mediated knockdown of the MPC in INS-1 cells and isolated rat islets reduced oxygen consumption rates, ATP content, and glucose-stimulated insulin secretion (GSIS) [@bib13]. While relatively little is known about the role of the MPC in human islet insulin secretion, this same study showed that MPC inhibition in isolated human islets produced effects similar to those seen in rat islets [@bib13]. In addition, mutant mice that carry a partial loss-of-function mutation in *Mpc2* are also hypoinsulinemic and glucose intolerant [@bib4]. These studies support the model that MPC function is required in the β-cell for GSIS and proper glucose homeostasis. Validation of this model *in vivo*, however, requires the characterization of the phenotypes associated with β-cell-specific MPC knockout. To complicate this issue further, recent work has shown that with marked depletion or even complete deletion of MPC proteins, adaptive mechanisms exist that can circumvent the block in pyruvate import [@bib3], [@bib14], [@bib15], [@bib16]. For instance, conversion of pyruvate into amino acids, especially alanine, was shown to support hepatic gluconeogenesis in liver MPC knockout mice by bypassing the need for MPC activity [@bib3], [@bib14]. Thus, we sought to evaluate the role of the MPC in GSIS in β-cells in a comprehensive manner by using both *Drosophila* and mouse models.

Herein, we demonstrate that the MPC plays a central role in GSIS and systemic glucose homeostasis. MPC deficiency in *Drosophila* or the β-cells of mice led to elevated blood glucose concentrations, glucose intolerance, and reduced GSIS. Pancreas-specific MPC deficiency resulted in impaired islet glucose metabolism and K~ATP~ channel hyperactivity. Moreover, treatment with the K~ATP~ channel inhibitor glibenclamide rescued the defects in GSIS both *in vitro* and *in vivo*. Finally, glucose increased MPC activity in cultured INS-1 cells in a concentration-dependent manner, suggesting that glucose sensing is coupled to mitochondrial pyruvate transport and utilization to support efficient GSIS. Taken together with previous work in human islets [@bib13], these data demonstrate an important and ancestral role for the MPC in glucose sensing and the regulation of insulin secretion that is conserved from *Drosophila* to humans.

2. Materials and methods {#sec2}
========================

2.1. Animal studies {#sec2.1}
-------------------

*Drosophila dMPC1* mutants (*dMPC1*^*1*^*/dMPC1*^*2*^ transheterozygotes) and genetically-matched precise-excision control strains have been described previously [@bib2]. Unless otherwise noted, experiments were conducted with 6--12 week old mice of both sexes. All vertebrate animal experiments were approved by the Animal Studies Committee of Washington University School of Medicine.

2.2. *Drosophila* dietary treatments {#sec2.2}
------------------------------------

*Drosophila* stocks were maintained on a standard cornmeal-molasses diet at 25 °C. To alter dietary sugar concentrations, media was prepared using either low (2% sucrose) or high (18%) sugar concentrations along with 10% yeast in water. For the lifespan studies, males were transferred to the indicated diet within one day of eclosion, then transferred to new vials every 2--5 days. To assay the effect of dietary sugar concentrations on metabolite levels, animals were raised on standard media and transferred to the indicated diet within 2--4 days of eclosion. Metabolites were measured within 8--12 days of transfer.

2.3. Fly metabolite measurements {#sec2.3}
--------------------------------

Whole-animal glucose, trehalose, triacylglycerol, glycogen, and protein measurements were performed using standard colorimetric assays [@bib17]. All other metabolites were measured by metabolomic profiling using gas chromatography/mass spectrometry as described [@bib17]. To measure circulating glucose in *Drosophila*, ∼30 adult females were punctured in the thorax with a tungsten needle and centrifuged at 13,000 g through DNA columns (Zymo- Spin IIIC \#C1006-50) twice in a centrifuge at 4 °C. Hemolymph was then diluted 1/200 in PBS and heat-treated at 70 °C for 10 min to inactivate enzymes, after which the glucose concentration was measured as described [@bib2].

2.4. Western blot analysis {#sec2.4}
--------------------------

To assay AKT phosphorylation, flies were aged for 8--12 days on high sugar media and then homogenized. Protein was resolved by SDS-PAGE and immunoblotted using standard methods with antibodies to phospho-AKT (Cell Signaling \#4691, 1:1000 dilution), pan-AKT (Cell Signaling \#4054, 1:1000 dilution), and beta-Tubulin (Chemicon MAB380, 1:100,000 dilution), followed by chemiluminescent detection.

2.5. Immunostaining of *Drosophila* insulin-producing cells (IPCs) {#sec2.5}
------------------------------------------------------------------

Brains were dissected in cold PBS and fixed for 20 min at room temperature in 4% paraformaldehyde in PBS. Following several washes in PAT (PBS + 0.5% Triton X-100) brains were blocked with 5% normal donkey serum overnight. Primary antibodies directed against DILP2 [@bib18] and dMPC1 [@bib5] were used at 1:500 concentration for 24 h at 4 °C. Rat Alexa 488-conjugated secondary antibodies (Jackson 212-545-168) and rabbit Cy3-conjugated secondary antibodies (Jackson 711-165-152) were used at 1:800 dilution at 4 °C. Brains were mounted in SlowFade Gold™ (Invitrogen) and imaged using an Olympus FV1000 confocal microscope. Z stack images were taken through the depth of fluorescence of the IPCs using identical settings.

2.6. DILP2 secretion assay {#sec2.6}
--------------------------

For measuring circulating DILP2 in *dMPC1* mutants, the HA-FLAG tagged DILP2 (DILP2-HF) transgene in a *dilp2*^*1*^ mutant background was recombined into a *dMPC1*^*1*^*/dMPC1*^*2*^ transheterozygote mutant background [@bib19]. To disrupt MPC function in the IPCs, *UAS-Dcr2; dilp2*^*1*^ *DILP2HF dilp2-GAL4/UAS-MPC1 RNAi; dilp2*^*1*^ *DILP2HF dilp2-GAL4* flies were used as described along with *dilp2*^*1*^ *DILP2HF* controls [@bib19]. Briefly, adult male progeny were fasted for 16 h and then fed 2 M glucose for 30 min. The posterior end of the abdomen was dissected to collect circulating hemolymph in PBS and the remaining carcasses were homogenized in PBS containing 1% Triton X-100 to assay for total remaining DILP2-HF. HA-FLAG peptide standards from 0, 20, 40 80, 160, 320 and 640 pg/ml were generated for a linear standard curve. 96-well ELISA plate (Thermo Scientific MaxiSorp Immulon 4 HBX, Cat\# 3855) coated with mouse anti-FLAG antibody (Sigma F1804, M2 monoclonal) and 1-Step Ultra TMB ELISA Substrate (Thermo Scientific 34029) were utilized for the ELISA assays. Circulating DILP2-HF (pg/fly) versus total remaining peptide was calculated to determine the percent secretion relative to controls (n ≥ 4 biological replicates per condition).

2.7. Generation of β-cell specific Mpc2 deficient mice {#sec2.7}
------------------------------------------------------

Mice harboring a conditional floxed *Mpc2* allele have been previously described [@bib3]. *Mpc2* floxed mice were crossed with mice expressing *Cre* recombinase driven by the rat insulin promoter [@bib20] (RipCreMpc2^−/−^ mice), the pancreatic and duodenal homeobox 1 (*Pdx1*) promoter [@bib21] (PdxCreMpc2^−/−^ mice), or a *Pdx1* promoter-driven tamoxifen-regulated Cre [@bib22] (PdxCre^ER^Mpc2^−/−^ mice). To conditionally-delete *Mpc2*, PdxCre^ER^Mpc2^−/−^ mice were injected i.p. with tamoxifen (50 μg/g body weight) for 5 consecutive days commencing at 5--6 weeks of age. Littermate *Mpc2* floxed mice not expressing *Cre* (fl/fl) were used for controls in all experiments.

2.8. Glucose and insulin tolerance tests {#sec2.8}
----------------------------------------

For the *Drosophila* glucose tolerance test (GTT), adult male flies were aged 5--9 days on standard media, fasted overnight on fasting media (1% agar in water), fed 10% glucose/1% agar for 2 h, and subsequently transferred to fasting media for two or 4 h. Glucose measurements were performed at each time point as described [@bib17]. Mouse glucose and insulin tolerance tests were performed as previously reported [@bib3], [@bib4].

2.9. Plasma insulin measurements {#sec2.9}
--------------------------------

Fifteen minutes post 1.5 g/kg body weight glucose bolus, mice were sacrificed by CO~2~ asphyxiation and blood was collected by cannulation of the inferior vena cava. Plasma was collected after blood centrifugation and insulin content was analyzed by Singulex assay by the Washington University Immunoassay Core of the Diabetes Research Center.

2.10. Pancreas immunohistochemistry {#sec2.10}
-----------------------------------

Insulin and glucagon protein abundance was assessed using paraffin-embedded pancreatic sections from WT, PdxCreMpc2−/−, and RipCreMpc2−/− mice. Slides were rehydrated, permeabilized with 1 mg/ml trypsin, blocked in 3% BSA, and probed with guinea pig anti-insulin (Abcam \#ab10988, 1:100 dilution) and mouse anti-glucagon (Abcam \#ab7842, 1:100 dilution) antibodies, in 3% BSA overnight. Slides were washed and probed with Alexa Fluor^®^ 488 goat anti-guinea pig (Invitrogen \#A11073, 1:1000 dilution) and Alexa Fluor^®^ 594 goat anti-mouse secondary (Invitrogen \#A21125, 1:1000 dilution) antibodies in 3% BSA for 1 h. Coverslips were fixed with ProLong^®^ Gold antifade reagent with DAPI (Life Technologies). Stained pancreatic sections were then imaged on an EVOS FL digital inverted fluorescence microscope (Invitrogen). Islet number and cross-sectional areas were determined using ImageJ.

2.11. Islet isolation and insulin secretion and rubidium efflux assays {#sec2.11}
----------------------------------------------------------------------

Islets were isolated from PdxCreMpc2−/− or PdxCre^ER^Mpc2−/− and littermate WT mice following cannulation of the pancreas with Hank\'s balanced salt solution containing collagenase as previously described [@bib4], [@bib23] and then maintained in RMPI 1640 media. After incubation with increasing glucose concentrations, insulin concentrations in the media were assayed by ELISA [@bib4]. Subsets of islets were treated with 30 mM KCl + 1 mM glucose, or 10 mM glutamine + 23 mM glucose. Insulin secretion treatments were performed in duplicate from 2 to 3 mice per genotype. For rubidium efflux assays, islets were preincubated for 6 h with culture media containing ^86^RbCl (1 μCi/mL). After stimulation with glucose, medium was aspirated and replaced with fresh solution at 5 min intervals. At 65 min, cells were lysed with 2% SDS. The amount of ^86^Rb^+^ in each aspirated solution and in final cell lysate was determined as previously described [@bib24]. Five experimental replicates were performed of the rubidium efflux assays using 2--3 mice of each genotype for each replicate.

2.12. Islet respiration assay {#sec2.12}
-----------------------------

Islets were isolated from PdxCreMpc2−/− and WT mice as above and 75 equal-sized islets were spun to the bottom of wells of Seahorse XF-24 plates. Oxygen consumption rates (OCR) were determined using an XF-24 Extracellular Flux Analyzer (Seahorse Bioscience) and normalized to protein content. Basal measurements were performed with 2 mM glucose and then islets were stimulated with 20 mM glucose. To characterize mitochondrial function, 1 μM oligomycin, 1.5 μM FCCP, and 1 μM antimycin A plus 100 nM rotenone were added sequentially. Islets were isolated and OCR measured from 4 to 5 mice per genotype.

2.13. REporter sensitive to PYRuvate (RESPYR) assay {#sec2.13}
---------------------------------------------------

pWPT lentiviral vectors expressing cDNA encoding human MPC2 fused to RLuc8 (BRET donor) and human MPC1 fused to Venus (BRET acceptor) [@bib25] were transduced into INS-1 cells. INS-1 cells were seeded in white 96-well plates 48 h before recording using RPMI 1640 media supplemented with 10% FBS, 5 mM sodium pyruvate, 10 mM [l]{.smallcaps}-glutamine and 0.25 mM β-mercaptoethanol. Medium was replaced with pyruvate- and glucose-free RPMI 4 h prior to assays, which were performed and analyzed as described [@bib25]. Luminescence was measured using a plate reader (Biotek Synergy 2) at 460 and 528 nm at 37 °C.

2.14. Statistical analyses {#sec2.14}
--------------------------

*P* values for pairwise comparisons were calculated using a Student\'s t test. *P* values for Kaplan Meier survival curves were calculated using a log rank test. *P* values for RESPYR curves were calculated using 2-way ANOVA coupled to Tukey\'s multiple comparison tests. In all experiments, *P* ≤ 0.05 was used to determine significant difference. All quantitative data is represented as mean ± SEM.

3. Results {#sec3}
==========

3.1. *Drosophila MPC1* null mutants exhibit elevated carbohydrates and premature death on a high-sugar diet {#sec3.1}
-----------------------------------------------------------------------------------------------------------

Our previous studies have shown that *Drosophila MPC1* null mutants on normal laboratory medium or a diet consisting of only sugar have elevated levels of glucose and the glucose disaccharide trehalose, which is consistent with the manifestation of diabetes in *Drosophila* [@bib2], [@bib26], [@bib27], [@bib28]. In addition, *dMPC1* mutants are sensitive to dietary sugar. Raising control flies on a low or high sugar diet (2% or 18% dietary sugar, respectively) has little effect on their lifespan ([Figure 1](#fig1){ref-type="fig"}A, left panel). In contrast, *dMPC1* mutants on the low sugar diet have approximately half the lifespan of controls ([Figure 1](#fig1){ref-type="fig"}A, purple curves), and this becomes significantly worse on the high sugar diet ([Figure 1](#fig1){ref-type="fig"}A, light blue curves). Analysis of whole-body metabolites demonstrated that *dMPC1* mutants display normal trehalose, glucose, and triglycerides on the low sugar diet, along with an increase in glycogen, but significantly elevated carbohydrates and decreased triglycerides on the high sugar diet ([Figure 1](#fig1){ref-type="fig"}B--E). This diet-dependent effect on carbohydrate levels is reminiscent of the beneficial impact of a ketogenic diet on diabetic patients.

To further examine the effect of diets on the metabolic state of *dMPC1* mutants, we conducted metabolomic profiling using small-molecule GC/MS ([Figure 2](#fig2){ref-type="fig"}). *dMPC1* mutants exhibit a significant accumulation of the sugars inositol, erythrose, and ribose as well as the sugar alcohols sorbitol, mannitol, threitol, and xylitol (or ribitol) when maintained on the high sugar diet. Conversion of excess intracellular glucose to sorbitol through the polyol pathway is thought to provide an alternative pathway for glucose clearance and storage and is associated with neuropathy in diabetic patients [@bib29]. In contrast, pyruvate accumulates to similar levels in *dMPC1* mutants on both diets ([Figure 2](#fig2){ref-type="fig"}). These metabolic changes on the high sugar diet demonstrate that *dMPC1* mutants are unable to maintain carbohydrate and lipid homeostasis in response to changes in dietary sugar.

3.2. *Drosophila MPC1* null mutants are glucose-intolerant with decreased insulin-like peptide secretion {#sec3.2}
--------------------------------------------------------------------------------------------------------

Consistent with the idea that *dMPC1* mutants suffer from an inherited form of diabetes, *dMPC1* mutants display elevated circulating glucose levels on the high sugar diet ([Figure 1](#fig1){ref-type="fig"}F), as well as fasting hyperglycemia ([Figure 1](#fig1){ref-type="fig"}G). Adult flies were subjected to an oral GTT by fasting control and *dMPC1* mutants overnight, transferring them to a 10% glucose diet for 2 h, and then re-fasting for two or 4 h. Although *dMPC1* mutants display a normal postprandial spike in free glucose levels after feeding, glucose clearance is significantly impaired in these animals, indicating glucose intolerance ([Figure 3](#fig3){ref-type="fig"}A). Taken together, these data indicate that *dMPC1* is required to maintain proper systemic glucose homeostasis and suppress diabetes.

Western blot analysis of *dMPC1* mutants revealed reduced whole-animal levels of phospho-AKT, indicating a decrease in systemic insulin signaling ([Figure 3](#fig3){ref-type="fig"}B). This observation raises the possibility that the defects in glucose homeostasis in *dMPC1* mutants could arise, at least in part, through defects in GSIS. *dMPC1* is expressed in the insulin producing cells (IPCs) of adult *Drosophila* as revealed by immunohistochemistry ([Figure 3](#fig3){ref-type="fig"}C). In addition, a direct assay to measure circulating levels of a tagged form of the major *Drosophila* Insulin-Like Peptide DILP2 (DILP2-HF) revealed that *dMPC1* mutants have no response to glucose feeding whereas control animals display a normal increase in circulating DILP2 ([Figure 3](#fig3){ref-type="fig"}D) [@bib19]. Finally, IPC-specific disruption of *dMPC1* expression by RNAi results in a significant reduction in GSIS relative to controls ([Figure 3](#fig3){ref-type="fig"}E). Whereas control flies show a ∼2.5-fold increase in circulating DILP2-HF from the fasted to fed state, flies lacking *dMPC1* in their IPCs show only a ∼1.5-fold response. These results indicate that the diabetic defects in *dMPC1* mutants arise, at least in part, from a defect in GSIS. Previous studies have shown that the *Drosophila* homologs of the K~ATP~ channel subunits Sur1 and Kir6 are active in adult IPCs and that these cells respond to glucose or glibenclamide treatment by undergoing calcium influx and membrane depolarization similar to mammalian pancreatic β-cells [@bib30]. Taken together with our studies of the MPC, this work suggests that efficient pyruvate oxidation in IPCs acts through the K~ATP~ channel to promote insulin release. Our studies of MPC function in mice, described below, support this model.

3.3. Loss of MPC2 in pancreas leads to glucose intolerance and impaired GSIS in mice {#sec3.3}
------------------------------------------------------------------------------------

We generated mice with deletion of *Mpc2* in pancreas by using the *Pdx* promoter to drive *Cre* expression in pancreatic pre-endoderm in mice with *Mpc2* floxed alleles. PdxCreMpc2−/− mice were outwardly normal and viable. Deletion of *Mpc2* did not affect islet number or cross-sectional area ([Figure 4](#fig4){ref-type="fig"}A and B), nor did it affect the intensity of staining for insulin or glucagon ([Figure 4](#fig4){ref-type="fig"}A). Like *dMPC1* mutants, PdxCreMpc2−/− mice were glucose intolerant in a GTT ([Figure 4](#fig4){ref-type="fig"}C). This was likely due to diminished insulin secretion, since insulin tolerance was unchanged by loss of MPC ([Figure 4](#fig4){ref-type="fig"}D) and plasma insulin concentration 15 min after a bolus glucose injection was significantly reduced compared to control mice ([Figure 4](#fig4){ref-type="fig"}E). Consistent with a defect in GSIS, islets isolated from PdxCreMpc2−/− mice exhibited reduced insulin secretion in response to 7 or 23 mM, but not 1 mM, glucose ([Figure 4](#fig4){ref-type="fig"}F). Stimulation of insulin secretion by 30 mM KCl or with addition of 10 mM glutamine, an alternate mitochondrial energy substrate, was not affected by loss of MPC2.

3.4. Conditional deletion of MPC in β cells also leads to glucose intolerance and β cell dysfunction {#sec3.4}
----------------------------------------------------------------------------------------------------

Previous work has demonstrated that some of the pancreas *Cre* drivers can have off-target or non-specific effects. These include gene recombination in the central nervous system [@bib31], [@bib32] and expression of human growth hormone due to the inclusion of a minigene encoding this secreted protein downstream of the *Cre* cDNA [@bib33]. Because of these issues, we verified the above findings using distinct β-cell *Cre* drivers. Deletion of *Mpc2* specifically in β-cells by using the rat insulin promoter-driven *Cre* also produced mice that were glucose intolerant ([Figure 5](#fig5){ref-type="fig"}A) with lower plasma insulin concentrations after bolus glucose injections ([Figure 5](#fig5){ref-type="fig"}B). *Mpc2* was also inducibly-deleted in β-cells by using a tamoxifen-activated Cre recombinase (*CreER*) driven by the Pdx promoter in mice that do not harbor the growth hormone minigene by injecting mice with 50 mg/kg tamoxifen on 5 consecutive days ([Figure 5](#fig5){ref-type="fig"}C). Eight weeks after tamoxifen injection, PdxCre^ER^Mpc2−/− mice were glucose intolerant ([Figure 5](#fig5){ref-type="fig"}D) and had lower blood insulin concentration 15 min after bolus glucose administration ([Figure 5](#fig5){ref-type="fig"}E) compared to littermate controls. Islets isolated from PdxCre^ER^Mpc2−/− mice exhibited reduced insulin secretion in response to 16 and 23 mM glucose, but not 1 and 7 mM glucose ([Figure 5](#fig5){ref-type="fig"}F).

3.5. MPC deficiency impairs GSIS via K~ATP~ channel hyperactivity {#sec3.5}
-----------------------------------------------------------------

To confirm that mitochondrial metabolism in high glucose conditions was diminished by MPC-deficiency, oxygen consumption rates in islets from WT and PdxCreMpc2−/− mice were assessed using a Seahorse XF analyzer. While basal (low glucose) respiration was unaffected, high glucose stimulated oxygen consumption rates were significantly reduced in PdxCreMpc2−/− islets compared to WT controls ([Figure 6](#fig6){ref-type="fig"}A). *Mpc2*-deficient islets responded normally to traditional respiration inhibitors and uncoupling ([Figure 6](#fig6){ref-type="fig"}A).

One mechanism by which increased glucose concentration is believed to regulate insulin secretion is via inhibition of K~ATP~ channel activity leading to membrane depolarization, Ca^2+^ influx, and insulin granule docking with the cell membrane and release. As a measure of K~ATP~ channel activity, we performed rubidium efflux (^86^RbCl) experiments (Rb^+^ as a surrogate for K^+^) [@bib23], [@bib34] using islets from PdxCreMpc2−/− and WT mice. ^86^Rb efflux was suppressed in a glucose concentration-dependent manner in WT islets ([Figure 6](#fig6){ref-type="fig"}B). However, the suppression of ^86^Rb efflux by higher glucose concentrations was impaired in islets from PdxCreMpc2−/− mice, suggesting K~ATP~ channel hyperactivity ([Figure 6](#fig6){ref-type="fig"}B).

We next assessed whether the sulfonylurea compound glibenclamide, which inhibits the K~ATP~ channel [@bib35], could uncouple pyruvate metabolism and membrane depolarization and therefore correct GSIS in Mpc2-deficient islets and mice. The defects in GSIS ([Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}F) and Rb^+^ efflux ([Figure 6](#fig6){ref-type="fig"}B) in Mpc2-deficient islets were reversed by incubation with glibenclamide. Moreover, the impairments in glucose intolerance and reduced plasma insulin concentration observed in PdxCreMpc2−/− mice were improved when glibenclamide was administered at the time of glucose bolus ([Figure 6](#fig6){ref-type="fig"}C and D). Altogether, these data suggest that the MPC complex and mitochondrial pyruvate metabolism regulates β-cell GSIS, at least in part, through regulation of K~ATP~ channel activity.

3.6. MPC activity is enhanced by high glucose in INS-1 cells {#sec3.6}
------------------------------------------------------------

Recent work using a BRET-based reporter assay for MPC activity (REporter Sensitive to PYRuvate; RESPYR) has suggested that MPC complex activity is acutely regulated [@bib25]. In this system, MPC2 protein is fused to modified Renilla luciferase (RLuc8; photon donor), while MPC1 is fused to a variant of yellow fluorescent protein (Venus; photon acceptor). Pyruvate transport induces a conformational change in the complex, reducing the distance between the donor and acceptor, and resulting in an increase in BRET ([Figure 7](#fig7){ref-type="fig"}A). Within minutes of administration, 7, 16, or 22 mM glucose increased the BRET signal compared to 0 or 1 mM glucose ([Figure 7](#fig7){ref-type="fig"}B) in INS-1 cells transduced with the RESPYR system. Glibenclamide had no effect on RESPYR activity ([Figure 7](#fig7){ref-type="fig"}B). The glucose concentration-dependent increase in RESPYR activity suggests that stimulation of MPC activity may be an important mediator of glucose sensing in insulin-producing cells.

4. Discussion {#sec4}
=============

Our studies of a complete loss of MPC function in *Drosophila* and mouse pancreatic β-cells have demonstrated an evolutionarily-conserved role for the MPC in insulin-producing cells to support GSIS and suppress hyperglycemia. Moreover, our mechanistic analyses support the model that mitochondrial pyruvate metabolism is critical for inhibition of K~ATP~ channel activity and insulin release and provide new evidence that MPC activity is acutely regulated by glucose concentration in insulin-producing cells. Our studies, together with previous work, place the MPC at a critical nexus in GSIS that is conserved through evolution, from flies to humans.

At high concentrations of glucose, islets isolated from PdxCreMpc2−/− mice exhibited deficits in oxygen consumption rates. Previous work has shown that ATP produced from pyruvate oxidation suppresses K~ATP~ channel activity [@bib36], [@bib37], [@bib38] and that genetic deletion of critical components of the pyruvate dehydrogenase complex, which is required for pyruvate oxidation, leads to overt hyperglycemia in mice [@bib39]. The alternative metabolic fate of pyruvate in the mitochondrion, carboxylation, has also been shown to play an important role in regulating insulin secretion via production of intermediates that stimulate insulin granule release by Ca^2+^-independent mechanisms [@bib7], [@bib10], [@bib11], [@bib12], [@bib40]. Because our genetic approach impacts both pyruvate oxidation and anaplerosis, it is not possible to distinguish which pathway is mediating the effects of MPC deficiency in β-cells. However, our studies assessing Rb^+^ efflux and using glibenclamide are consistent with the idea that K~ATP~ channel hyperactivity is at least partially responsible for the phenotype of these mice.

The present studies, together with other recent work, illustrate interesting species-specific and tissue-specific effects of MPC deficiency. *Drosophila MPC1* mutants developed more severe diabetic phenotypes than pancreas-specific *Mpc2* knockout mice, including more severe glucose intolerance. This is likely due to the systemic loss of MPC function in the *Drosophila* whole-animal mutants. Impaired mitochondrial pyruvate metabolism in glucose-utilizing myocytes or neurons might be predicted to impair glucose disposal. On the other hand, knockout of *Mpc1* or *Mpc2* in the liver of mice leads to hypoglycemia and protects mice from the development of diabetes [@bib3], [@bib14]. Pyruvate is a substrate for gluconeogenesis in hepatocytes and mitochondrial metabolism of pyruvate is required to convert pyruvate to new glucose, which contributes to hyperglycemia of diabetes when insulin is insufficient to suppress gluconeogenesis [@bib3]. Thus, while the MPC could be considered an intriguing target for antidiabetic drugs, it is important to emphasize that it will be necessary to identify agents that act in a tissue-specific manner to ensure the intended effect. Targeting MPC function to improve β-cell GSIS would have to be performed with caution as increasing MPC activity in the liver would likely increase gluconeogenesis and worsen hyperglycemia [@bib3], [@bib14].

The MPC is amenable to pharmacological targeting. A number of specific MPC inhibitors (e.g. UK-5099) were identified years ago [@bib41]. Interestingly, experimental thiazolidine compounds studied as K~ATP~ channel inhibitors can also act in an inhibitory fashion on the MPC [@bib42]. More recently, thiazolidinedione (TZD) insulin-sensitizers (rosiglitazone, pioglitazone, MSDC-0602, and MSDC-0160) were shown to bind to [@bib3], [@bib5] and inhibit the MPC [@bib3], [@bib43]. However, it should be noted that treatment of primary human islets with MSDC-0160 did not affect GSIS and enhanced islet survival and insulin expression [@bib44] in contrast with the results obtained with other genetic or pharmacologic inhibition studies [@bib4], [@bib13].

Lastly and importantly, using a recently-developed BRET-based sensor, our studies in INS-1 cells demonstrated that increasing concentrations of glucose dose-dependently increased MPC activity. This could suggest that the activity of this complex is a mechanistic detector of glucose concentration that contributes to the ability of β-cells to "sense" glucose. Future studies will be needed to determine whether the activity of this complex is deranged in insulin resistance and in type 2 diabetes and, if so, at what regulatory levels the complex is affected. It also remains to be determined whether genetic mutation or variations in the MPC could influence the onset of relative hypoglycemia that leads to diabetes. We believe that the MPC may be an important target to pharmacologically-enhance GSIS in insulin-resistant states and develop new classes of anti-diabetic drugs.
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![*Drosophila MPC1* mutants are hyperglycemic and sensitive to dietary sugar. A*: dMPC1* mutants die more rapidly as dietary sugar is increased. The percentage of surviving adult control (left panel) or *dMPC1* mutants (right panel) fed a low (2% sucrose, 10% yeast; purple lines) or high (18% sucrose, 10% yeast; light blue lines) sugar diet was assayed every 2--5 days. N \> 115 male flies per genotype under each feeding condition. Mean ± SEM is shown. B--E: Control (blue) or *dMPC1* mutants (red) were aged 8--12 days on the low or high sugar diet and whole animal metabolite levels were measured to determine the abundance of B: trehalose C: glucose, D: glycogen, or E: triglycerides (TAG), all normalized to protein. N = 5--6 samples per genotype. Mean ± SEM is shown. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001. F: Hemolymph glucose concentrations were determined in control and *dMPC1* mutants aged 10 days on the high sugar media. N = 4 per genotype. \*\*p \< 0.01 G: Control and *dMPC1* mutants were aged 5--9 days on standard laboratory media and fasted overnight for 16 h. After fasting, whole-animal glucose levels were determined and normalized to protein. N = 5 per genotype. \*\*p \< 0.01.](gr1){#fig1}

![Sugars and sugar alcohols accumulate in *dMPC1* mutants in response to dietary sugar. Control (blue) or *dMPC1* mutants (*dMPC1*^*--*^)(red) were aged 8--12 days on the low or high sugar diets and whole animal metabolite levels were measured by GC/MS. The abundance of pyruvate, ribose, inositol, erythrose, sorbitol, mannitol, threitol, and xylitol or ribitol (which cannot be distinguished in our analysis) is shown. N = 3 biological replicates per condition. Mean ± SEM is shown. P values comparing mutants to controls under either condition were calculated by Student\'s t test. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001.](gr2){#fig2}

![*Drosophila MPC1* mutants are glucose intolerant and have reduced glucose-stimulated insulin secretion. A: Oral-glucose tolerance test performed on adult control (blue) and *dMPC1* mutants (red) that were aged 5--9 days on standard laboratory media, fasted overnight, fed 10% glucose for 2 h, and then re-fasted for either 2 or 4 h. Data represents free glucose levels from whole animal homogenates normalized to protein concentration. N = 5 biological replicates per genotype at each timepoint. Mean ± SEM is shown. \*p \< 0.05 and \*\*\*p \< 0.001. B: Control and *dMPC1* mutants were aged 8--12 days on the high sugar diet and phosphorylated AKT (P-AKT), total AKT, and tubulin protein levels were determined by western blot analysis. C: The insulin-producing cells (IPCs) embedded in the adult brain were stained with antibodies directed against either DILP2 (left, red) or MPC1 (green, center) in either control or *dMPC1* mutants. *dMPC1* staining is evident in the IPCs of control, but not mutant, flies. *D: dMPC1* mutants display defects in GSIS. Control and *dMPC1* mutants carrying DILP2-HF in a *dilp2*^*1*^ mutant background were aged 5--9 days on standard laboratory media, fasted overnight, and fed glucose for 30 min. Hemolymph was collected to measure circulating DILP2-HF under fasted and fed conditions. Y axis depicts the ratio of secreted DILP2-HF to total DILP2-HF. (fasted n = 4, fed n = 5). \*\*p ≤ 0.01. NS = not significant. E: IPC-specific *dMPC1* RNAi results in reduced GSIS. Levels of circulating DILP2-HF were assayed in controls (blue) or animals with IPC-specific RNAi against *dMPC1* (red) using a *dilp2-GAL4* driver. \*p \< 0.05, \*\*p ≤ 0.01.](gr3){#fig3}

![*Mice with pancreas-specific MPC2 deletion have reduced GSIS despite normal insulin content*. A: Immunohistochemical staining of islets showed no difference in immunodetectable insulin, glucagon, or β and α cell number. B: Histologic assessment of islet number and individual cross-sectional area detected no difference between WT and PdxCreMpc2−/− mice. C: Mice were fasted for 16 h and injected i.p. with 1.5 g/kg glucose. PdxCreMpc2−/− mice displayed significantly elevated blood glucose concentrations after the overnight fast and after bolus glucose injection. D: Mice were fasted for 4 h and injected i.p. with 0.5 U/kg insulin. PDXCreMpc2−/− mice displayed elevated basal blood glucose levels but similar insulin response curves. E: Plasma insulin concentrations were reduced in PdxCreMpc2−/− mice 15 min after bolus glucose injection. F: Loss of Mpc2 in beta cells impairs GSIS by isolated islets. Isolated islets from WT and PdxCreMpc2−/− mice were incubated with the indicated concentrations of glucose and insulin concentration of the medium determined. Insulin secretion was corrected in PdxCreMpc2−/− islets with either 1 μM glibenclamide treatment or stimulation with 30 mM KCl + 1 mM glucose. 10 mM glutamine + 23 mM glucose-stimulated insulin secretion was also normal. N = 10--12 mice per genotype with 10 pancreas sections analyzed per mouse in A and B. N = 10--13 mice per genotype in C and D. N = 5--6 mice per genotype in E. N = 2--3 mice per genotype and two technical replicates per mouse in F. Mean ± SEM is shown. P values comparing KOs to controls were calculated using a Student\'s t test. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001, ^Ϯ^p \< 0.05 compared to non-glib treatment.](gr4){#fig4}

![*Constitutive or Tamoxifen-inducible deletion of Mpc2 in pancreatic β-cells results in defective glucose-stimulated insulin secretion*. A: Mice were fasted for 16 h and injected i.p. with 1.5 g/kg glucose. RipCreMpc2−/− mice display elevated blood glucose concentrations following bolus glucose injection. B: Plasma insulin concentration of RipCreMPC2−/− mice is reduced 15 min after bolus glucose injection C: Schematic of Tamoxifen-inducible Mpc2 deletion in PdxCre^ER^Mpc2−/− mice. Tamoxifen dose was 50 mg/kg i.p. for 5 consecutive days. D: Mice were fasted for 16 h and injected i.p. with 1.5 g/kg glucose. PdxCre^ER^Mpc2−/− mice displayed elevated blood glucose concentration during the GTT. Glucose AUC was also significantly elevated. E: Plasma insulin concentrations of PdxCre^ER^Mpc2−/− mice were reduced 15 min after i.p. injection of 1.5 g/kg glucose following a 6 h fast. F: Isolated islets from PdxCre^ER^Mpc2−/− mice contain normal insulin content, but defective glucose-stimulated insulin secretion. Insulin secretion was corrected in PdxCre^ER^Mpc2−/− islets with either 1 μM Glibenclamide treatment or stimulation with 30 mM KCl + 1 mM glucose, suggesting the defect prior to the membrane depolarization. N = 5--7 mice per group in A, B, and E. N = 11--12 mice per genotype in D, and N = 2--3 mice per genotype and two technical replicates per mouse in F. Mean ± SEM is shown. P values comparing KOs to controls were calculated using a Student\'s t test. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001, ^Ϯ^p \< 0.05 compared to non-glib treatment.](gr5){#fig5}

![*Defects in MPC2 KO islet K*~*ATP*~*channel activity and GSIS are correctable with sulfonylurea treatment. A*: Isolated islets were stimulated with glucose and oxygen consumption rates (OCR) were determined. PdxCreMpc2−/− islets display reduced OCR in response to 20 mM glucose stimulation, but maintain similar responsiveness to oligomycin, FCCP, and Antimycin A + Rotenone treatment. B: PdxCreMpc2−/− islets display increased K~ATP~ channel activity in response to glucose stimulation. ^86^Rb^+^ efflux was measured in cultured islets following stimulation with glucose (7 mM or 16.7 mM) or glucose plus glibenclamide (16.7 mM + glib). C: Blood glucose concentrations during the GTT performed using fl/fl and PdxCreMpc2−/− mice. Mice were fasted for 16 h and injected i.p. with 1.5 g/kg glucose and co-injected with vehicle or the K~ATP~ channel inhibitor glibenclamide (0.1 mg/kg). D: Glibenclamide also corrected plasma insulin concentrations 15 min after glucose injection in PdxCreMpc2−/− mice. N = 4--5 mice per genotype in A, N = 5 experimental replicates using islets from 2 to 3 mice per genotype in B, N = 13--14 mice per GTT group in C, and N = 6 per insulin secretion group in D. \*p \< 0.05, ^Ϯ^p \< 0.05 compared to vehicle treatment.](gr6){#fig6}

![*Glucose stimulation increases MPC activity in INS-1 cells*. *A*: Schematic of the BRET-based RESPYR biosensor used to measure real time activity of the mitochondrial pyruvate carrier. RLuc8 is c-terminally fused to MPC2 and Venus is c-terminally fused to MPC1. BRET signal increases above basal levels as carrier transport activity increases. B: BRET kinetics of INS-1 cells expressing RESPYR. Cells were stimulated after 5 min with PBS (black squares), 1 mM glucose (gray circles), 7 mM glucose (blue rectangles), 16.7 mM glucose (green diamonds) or 22 mM glucose (red circles) or 1 μM glibenclamide (purple triangles) in PBS. Data were analyzed by repeated measures ANOVA in Prism. Post Hoc analysis was performed using Tukey\'s multiple comparison tests. Data represents mean ± SEM of six independent experiments with 4--5 technical replicates per experiment.\*p \< 0.05 compared to PBS, 1 mM glucose and 1 μM glib treatments, ^Ϯ^p \< 0.05 compared to all other treatments.](gr7){#fig7}
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